Antagonists of GPR35 display high species ortholog selectivity and varying modes of action

Journal of Pharmacology and Experimental Therapeutics

Volumn 343, Issue 3, 2012, Pages 683-695

  Jenkins, Laura ^a   Harries, Nicholas ^a   Lappin, Jennifer E ^a   MacKenzie, Amanda E ^a   Neetoo Isseljee, Zaynab ^b   Southern, Craig ^b   McIver, Edward G ^b   Nicklin, Stuart A ^a   Taylor, Debra L ^b   Milligan, Graeme ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXY 4 [4 [5 (2 METHYL 3 PHENYLPROP 2 ENYLIDENE) 4 OXO 2 SULFANYLIDENE 1,3 THIAZOLIDIN 3 YL]BUTANOYLAMINO]BENZOIC ACID; BETA ARRESTIN 2; CID 2745687; CROMOGLYCATE DISODIUM; EMBONIC ACID; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 35; METHYL 5 [(TERT BUTYLCARBAMOTHIOYLHYDRAZINYLIDENE)METHYL] 1 (2,4 DIFLUOROPHENYL)PYRAZOLE 4 CARBOXYLATE; ML 145; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; ZAPRINAST;

ARTICLE; BINDING AFFINITY; BINDING SITE; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; CELL STRAIN HEK293; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; EMBRYO; HUMAN; HUMAN TISSUE; INTERNALIZATION; LIGAND BINDING; MOLECULAR INTERACTION; MOUSE; NONHUMAN; ORTHOLOGY; PRIORITY JOURNAL; RAT; SEQUENCE ALIGNMENT; SPECIES DIFFERENCE;

AMINOSALICYLIC ACIDS; ANIMALS; ARRESTINS; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER TECHNIQUES; CELL CULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG PARTIAL AGONISM; HEK293 CELLS; HUMANS; HYDRAZONES; LIGANDS; MICE; MICROSCOPY, FLUORESCENCE; MOLECULAR STRUCTURE; PROTEIN BINDING; RATS; RECEPTORS, G-PROTEIN-COUPLED; SPECIES SPECIFICITY; THIAZOLIDINES; THIOUREA; TRANSFECTION;

EID: 84869207630     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.198945     Document Type: Article

References (34)

1. Arch JR (2008) The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology: perspectives from β3-adrenoceptor agonists. Naunyn Schmiedebergs Arch Pharmacol 378:225-240.
2. Barth MC, Ahluwalia N, Anderson TJ, Hardy GJ, Sinha S, Alvarez-Cardona JA, Pruitt IE, Rhee EP, Colvin RA, and Gerszten RE (2009) Kynurenic acid triggers firm arrest of leukocytes to vascular endothelium under flow conditions. J Biol Chem 284:19189-19195.
3. Cosi C, Mannaioni G, Cozzi A, Carlà V, Sili M, Cavone L, Maratea D, and Moroni F (2011) G-protein coupled receptor 35 (GPR35) activation and inflammatory pain: Studies on the antinociceptive effects of kynurenic acid and zaprinast. Neuropharmacology 60:1227-1231.
4. Coward P, Chan SD, Wada HG, Humphries GM, and Conklin BR (1999) Chimeric G proteins allow a high-throughput signaling assay of Gi-coupled receptors. Anal Biochem 270:242-248. (Pubitemid 29252535)
5. Deng H and Fang Y (2012) Aspirin metabolites are GPR35 agonists. Naunyn Schmiedebergs Arch Pharmacol 385:729-737.
6. Deng H, Hu H, and Fang Y (2011) Tyrphostin analogs are GPR35 agonists. FEBS Lett 585:1957-1962.
7. Deng H, Hu H, and Fang Y (2012) Multiple tyrosine metabolites are GPR35 agonists. Sci Rep 2:373.
8. de Souza CJ and Burkey BF (2001) β3-Adrenoceptor agonists as anti-diabetic and anti-obesity drugs in humans. Curr Pharm Des 7:1433-1449. (Pubitemid 32798819)
9. DeWire SM, Ahn S, Lefkowitz RJ, and Shenoy SK (2007) β-Arrestins and cell signaling. Annu Rev Physiol 69:483-510.
10. Emkey R and Rankl NB (2009) Screening G protein-coupled receptors: measurement of intracellular calcium using the fluorometric imaging plate reader. Methods Mol Biol 565:145-158.
11. Hamdan FF, Audet M, Garneau P, Pelletier J, and Bouvier M (2005) High-throughput screening of G protein-coupled receptor antagonists using a bioluminescence resonance energy transfer 1-based β-arrestin2 recruitment assay. J Biomol Screen 10:463-475. (Pubitemid 41233225)
12. Heynen-Genel S, Dahl R, Shi S, Sauer M, Hariharan S, Sergienko E, Dad S, Chung TDY, Stonich D, Su Y, et al. (2010) Selective GPR35 Antagonists: Probes 1 and 2. Probe Reports from the NIH Molecular Libraries Program, Bethesda, MD. National Center for Biotechnology Information, Bethesda, MD. [updated Oct 4 2010].
13. Hu H, Deng H, and Fang Y (2012) Label-free phenotypic profiling identified D-luciferin as a GPR35 agonist. PLoS One 7:e34934.
14. Jenkins L, Alvarez-Curto E, Campbell K, de Munnik S, Canals M, Schlyer S, and Milligan G (2011) Agonist activation of the G protein-coupled receptor GPR35 involves transmembrane domain III and is transduced via Gα and β-arrestin-2. Br J Pharmacol 162:733-748.
15. Jenkins L, Brea J, Smith NJ, Hudson BD, Reilly G, Bryant NJ, Castro M, Loza MI, and Milligan G (2010) Identification of novel species-selective agonists of the G-protein-coupled receptor GPR35 that promote recruitment of β-arrestin-2 and activate Gα13. Biochem J 432:451-459.
16. Kostenis E, Waelbroeck M, and Milligan G (2005) Techniques: promiscuous Gα proteins in basic research and drug discovery. Trends Pharmacol Sci 26:595-602. (Pubitemid 41505228)
17. Lim HD, de Graaf C, Jiang W, Sadek P, McGovern PM, Istyastono EP, Bakker RA, de Esch IJ, Thurmond RL, and Leurs R (2010) Molecular determinants of ligand binding to H4R species variants. Mol Pharmacol 77:734-743.
18. Liu C, Wilson SJ, Kuei C, and Lovenberg TW (2001) Comparison of human, mouse, rat, and guinea pig histamine H4 receptors reveals substantial pharmacological species variation. J Pharmacol Exp Ther 299:121-130. (Pubitemid 32905126)
19. Luttrell LM and Kenakin TP (2011) Refining efficacy: allosterism and bias in G protein-coupled receptor signaling. Methods Mol Biol 756:3-35.
20. MacKenzie AE, Lappin JE, Taylor DL, Nicklin SA, and Milligan G (2011) GPR35 as a novel therapeutic target. Front Endocrinol (Lausanne) 2:68.
21. Milligan G (2011) Orthologue selectivity and ligand bias: translating the pharmacology of GPR35. Trends Pharmacol Sci 32:317-325.
22. Milligan G and Kostenis E (2006) Heterotrimeric G-proteins: a short history. Br J Pharmacol 147 (Suppl 1):S46-S55. (Pubitemid 43077261)
23. Milligan G and Rees S (1999) Chimaeric Gα proteins: their potential use in drug discovery. Trends Pharmacol Sci 20:118-124. (Pubitemid 29306936)
24. Min KD, Asakura M, Liao Y, Nakamaru K, Okazaki H, Takahashi T, Fujimoto K, Ito S, Takahashi A, Asanuma H, et al. (2010) Identification of genes related to heart failure using global gene expression profiling of human failing myocardium. Biochem Biophys Res Commun 393:55-60.
25. Ohshiro H, Tonai-Kachi H, and Ichikawa K (2008) GPR35 is a functional receptor in rat dorsal root ganglion neurons. Biochem Biophys Res Commun 365:344-348. (Pubitemid 350137295)
26. Oka S, Ota R, Shima M, Yamashita A, and Sugiura T (2010) GPR35 is a novel lysophosphatidic acid receptor. Biochem Biophys Res Commun 395:232-237.
27. Schnell D, Brunskole I, Ladova K, Schneider EH, Igel P, Dove S, Buschauer A, and Seifert R (2011) Expression and functional properties of canine, rat, and murine histamine H4 receptors in Sf9 insect cells. Naunyn Schmiedebergs Arch Pharmacol 383:457-470.
28. Schröder R, Schmidt J, Blättermann S, Peters L, Janssen N, Grundmann M, Seemann W, Kaufel D, Merten N, Drewke C, et al. (2011) Applying label-free dynamic mass redistribution technology to frame signaling of G protein-coupled receptors non-invasively in living cells. Nat Protoc 6:1748-1760.
29. Taniguchi Y, Tonai-Kachi H, and Shinjo K (2006) Zaprinast, a well-known cyclic guanosine monophosphate-specific phosphodiesterase inhibitor, is an agonist for GPR35. FEBS Lett 580:5003-5008. (Pubitemid 44332369)
30. Verkaar F, van Rosmalen JW, Blomenröhr M, van Koppen CJ, Blankesteijn WM, Smits JF, and Zaman GJ (2008) G protein-independent cell-based assays for drug discovery on seven-transmembrane receptors. Biotechnol Annu Rev 14:253-274. (Pubitemid 351916584)
31. Wang J, Simonavicius N, Wu X, Swaminath G, Reagan J, Tian H, and Ling L (2006) Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem 281:22021-22028. (Pubitemid 44181906)
32. Yang Y, Fu A, Wu X, and Reagan JD (2012) GPR35 is a target of the loop diuretic drugs bumetanide and furosemide. Pharmacology 89:13-17.
33. Yang Y, Lu JY, Wu X, Summer S, Whoriskey J, Saris C, and Reagan JD (2010) G-protein-coupled receptor 35 is a target of the asthma drugs cromolyn disodium and nedocromil sodium. Pharmacology 86:1-5.
34. Zhao P, Sharir H, Kapur A, Cowan A, Geller EB, Adler MW, Seltzman HH, Reggio PH, Heynen-Genel S, Sauer M, et al. (2010) Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and β-arrestin2 with antinociceptive activity. Mol Pharmacol 78:560-568.